Evidence map›Paper›PMID 39120885›Full record

ArticleTranslational vision science & technology2024

Report From the Second Global Scientific Conference on Clinical Trial Design and Outcome Measures for RDH12-Associated Inherited Retinal Degeneration.

Silvia Cerolini, Jean Bennett, Bart P Leroy, Todd Durham, Courtney Coates, Mathew T Pletcher, Sue Lacey, Tomas S Aleman

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvia CeroliniEyes on the Future, London, UK.
Jean BennettScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bart P LeroyDepartment of Ophthalmology and Center for Medical Genetics, Ghent University Hospital and Department of Head & Skin, Ghent University, Ghent, Belgium.
Todd DurhamFoundation Fighting Blindness, Columbia, MD, USA.
Courtney CoatesHope in Focus, Ledyard, CT, USA.
Mathew T PletcherRDH12 Fund for Sight, Boiling Springs, SC, USA.
Sue LaceyAstraea Medical Consulting, Hindhead, UK.
Tomas S AlemanScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Translational Relevance: A multi-stakeholder, patient centric approach will be critical to the design of future successful clinical trials with outcome measures relevant to the RDH12-IRD population.

Indexed as

Alcohol OxidoreductasesClinical Trials as TopicRetinal DegenerationHumansOutcome Assessment, Health CareResearch DesignAlcohol OxidoreductasesRDH12 protein, human

Identifiers

PMID39120885
PMCPMC11318357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.